[go: up one dir, main page]

WO2009121600A3 - Hydroxytyrosol formulations for the treatment and prevention of dna oxidative damages in post-menopausal conditions - Google Patents

Hydroxytyrosol formulations for the treatment and prevention of dna oxidative damages in post-menopausal conditions Download PDF

Info

Publication number
WO2009121600A3
WO2009121600A3 PCT/EP2009/002416 EP2009002416W WO2009121600A3 WO 2009121600 A3 WO2009121600 A3 WO 2009121600A3 EP 2009002416 W EP2009002416 W EP 2009002416W WO 2009121600 A3 WO2009121600 A3 WO 2009121600A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxytyrosol
formulations
extract
prevention
post
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/002416
Other languages
French (fr)
Other versions
WO2009121600A2 (en
Inventor
Felicia Cisale
Luciano Villanova
Azzura Villanova
Alessandro Merendino
Gianluca Fasiello
Luigi Villanova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lachifarma Srl Laboratorio Chimico Farmaceutico Salentino
Original Assignee
Lachifarma Srl Laboratorio Chimico Farmaceutico Salentino
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lachifarma Srl Laboratorio Chimico Farmaceutico Salentino filed Critical Lachifarma Srl Laboratorio Chimico Farmaceutico Salentino
Publication of WO2009121600A2 publication Critical patent/WO2009121600A2/en
Publication of WO2009121600A3 publication Critical patent/WO2009121600A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/742—Coffea, e.g. coffee
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical or dietetic formulations comprising hydroxytyrosol and at least one of the following components: - Angelica sinensis extract; - Salvia officinalis extract; - Passion fruit extract; - Olea europea extract; - Dioscorea extract; - calcium and/or magnesium ions; - vitamin D; - one or more biophenol and/or carotenoid compounds.
PCT/EP2009/002416 2008-04-04 2009-04-02 Hydroxytyrosol formulations for the treatment and prevention of dna oxidative damages in post-menopausal conditions Ceased WO2009121600A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TCMI2008A000589 2008-04-04
IT000589A ITMI20080589A1 (en) 2008-04-04 2008-04-04 HYDROXYSEROSOL FORMULATIONS ONLY FOR THE PREVENTIVE AND CURATIVE TREATMENT OF DAMAGES PRODUCED BY THE OXIDATIVE EFFECTS ON THE DNA IN POST-MENOPAUSAL SITUATIONS

Publications (2)

Publication Number Publication Date
WO2009121600A2 WO2009121600A2 (en) 2009-10-08
WO2009121600A3 true WO2009121600A3 (en) 2010-01-21

Family

ID=40296854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/002416 Ceased WO2009121600A2 (en) 2008-04-04 2009-04-02 Hydroxytyrosol formulations for the treatment and prevention of dna oxidative damages in post-menopausal conditions

Country Status (2)

Country Link
IT (1) ITMI20080589A1 (en)
WO (1) WO2009121600A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2848552T3 (en) 2013-04-05 2021-08-10 Nestle Sa Compositions to stimulate bone growth
CN103599239B (en) * 2013-11-01 2015-05-06 于明儒 Traditional Chinese medicine ointment for treating osteoporosis
IT201900000343A1 (en) * 2019-01-10 2020-07-10 Herbal E Antioxidant Derivatives S R L Ed In Forma Abbreviata H&Ad S R L COMPOSITIONS FOR THE TREATMENT OF MENOPAUSE, OSTEOPENIA AND OSTEOPOROSIS, METABOLIC AND VASCULAR DISORDERS RELATED TO CLIMATER
WO2020229539A1 (en) * 2019-05-13 2020-11-19 Société des Produits Nestlé S.A. Compositions and methods using a combination of calcium and at least one of oleuropein or metabolite thereof
KR20230074226A (en) * 2020-09-24 2023-05-26 마아즈, 인코오포레이티드 Food Compositions and Uses Thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1623960A1 (en) * 2004-08-06 2006-02-08 Lachifarma SRL Laboratorio Chimico Farmaceutico Salentino Process for the recovery of tyrosol and hydroxytyrosol from oil mill wastewaters and catalytic oxidation method in order to convert tyrosol in hydroxytyrosol
US20070154532A1 (en) * 2003-12-30 2007-07-05 Med Care S.R.L. Compositions comprising vitamins and/or derivatives thereof stablished with olea europea extract and/or ionene polymers
WO2008006581A2 (en) * 2006-07-14 2008-01-17 Dsm Ip Assets B.V. Compositions and use thereof for the treatment, co-treatment or prevention of imflammatory disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070154532A1 (en) * 2003-12-30 2007-07-05 Med Care S.R.L. Compositions comprising vitamins and/or derivatives thereof stablished with olea europea extract and/or ionene polymers
EP1623960A1 (en) * 2004-08-06 2006-02-08 Lachifarma SRL Laboratorio Chimico Farmaceutico Salentino Process for the recovery of tyrosol and hydroxytyrosol from oil mill wastewaters and catalytic oxidation method in order to convert tyrosol in hydroxytyrosol
WO2008006581A2 (en) * 2006-07-14 2008-01-17 Dsm Ip Assets B.V. Compositions and use thereof for the treatment, co-treatment or prevention of imflammatory disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
PUEL C ET AL: "Black Lucques olives prevented bone loss caused by ovariectomy and talc granulomatosis in rats", BRITISH JOURNAL OF NUTRITION 200705 GB,, vol. 97, no. 5, 1 May 2007 (2007-05-01), pages 1012 - 1020, XP002537642 *
SALVINI SIMONETTA ET AL: "Daily consumption of a high-phenol extra-virgin olive oil reduces oxidative DNA damage in postmenopausal women", BRITISH JOURNAL OF NUTRITION, vol. 95, no. 4, April 2006 (2006-04-01), pages 742 - 751, XP008114939, ISSN: 0007-1145 *
SONI M G ET AL: "Safety assessment of aqueous olive pulp extract as an antioxidant or antimicrobial agent in foods", FOOD AND CHEMICAL TOXICOLOGY, PERGAMON, GB, vol. 44, no. 7, 1 July 2006 (2006-07-01), pages 903 - 915, XP025065576, ISSN: 0278-6915, [retrieved on 20060701] *
STUPANS I ET AL: "COMPARISON OF RADICAL SCAVENGING EFFECT, INHIBITION OF MICROSOMAL OXYGEN FREE RADICAL GENERATION, AND SERUM LIPOPROTEIN OXIDATION OF SEVERAL NATURAL ANTIOXIDANTS", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 50, no. 8, 10 April 2002 (2002-04-10), pages 2464 - 2469, XP001128117, ISSN: 0021-8561 *
TRIPOLI E ET AL: "THE PHENOLIC COMPOUNDS OF OLIVE OIL: STRUCTURE, BIOLOGICAL ACTIVITY AND BENEFICIAL EFFECTS ON HUMAN HEALTH", NUTRITION RESEARCH REVIEWS, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 18, no. 1, 1 January 2005 (2005-01-01), pages 98 - 112, XP009070306, ISSN: 0954-4224 *

Also Published As

Publication number Publication date
ITMI20080589A1 (en) 2009-10-05
WO2009121600A2 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
IL291175A (en) Compositions and methods for treating collagen-mediated diseases
IL269370B (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2007081729A3 (en) Treatment modalities for autoimmune diseases
IL207038A (en) Diazaspiro[5.5]undecane derivatives, pharmaceutical compositions comprising the same and uses thereof in the preparation of medicaments for treating or reducing the risk of an inflammatory disease or condition
MX2017009532A (en) Use of short chain fatty acids in cancer prevention.
IL192967A0 (en) Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2008122965A3 (en) Pharmaceutical cyclosporin compositions
FR2953135B1 (en) MACROSTACHYA ACACIA SEED EXTRACT AND COSMETIC, PHARMACEUTICAL, DERMATOLOGICAL, NUTRACEUTICAL OR FOOD COMPOSITIONS COMPRISING THE SAME
WO2008006589A3 (en) Compositions comprising rosehip and other active agents for the treatment of inflammatory disorders
BRPI1014824A2 (en) pharmaceutical composition in unit dose form and method of treating, preventing or reducing the occurrence of a condition in an individual
WO2011018501A3 (en) Composition including an unsaponifiable fraction
EP2192901A4 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2009121600A3 (en) Hydroxytyrosol formulations for the treatment and prevention of dna oxidative damages in post-menopausal conditions
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
EP2274411A4 (en) Xanthohumol compositions and methods for treating skin diseases or disorders
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
EP2040726A4 (en) Trachelospermi caulis extract composition for the treatment and prevention of inflammatory diseases
ZA200706286B (en) Pharmaceutical composition for treating nephropathy and healthy food comprising herb extracts
WO2012050398A3 (en) Pharmaceutical composition including herbal medicine extract for preventing or treating lung cancer
IL215840A (en) 2,5-disubstituted arylsulfonamide compounds, pharmaceutical compositions comprising same and use thereof in treating ccr3-related diseases
WO2011043631A3 (en) Pharmaceutical composition for preventing and treating cold, containing reynoutria elliptica extract, fraction thereof or stilbene-based compound
WO2010068815A3 (en) Compositions and methods for treating cellular proliferative disorders
WO2008039409A8 (en) Methods and kits for use in the treatment and prevention of diseases or conditions of the immune system or infectious diseases
WO2010147814A3 (en) Combinations of herb extracts having synergistic antioxidant effect, and methods relating thereto
WO2009044010A3 (en) Use of at least one oxime derivative of cholest-4-en-3-one as antioxidants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09726944

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09726944

Country of ref document: EP

Kind code of ref document: A2